Key facts
- Sword Bio’s last known valuation is $9.9M (Mar 2018).
- It has raised $10.2M; the latest was Angel (individual) in Oct 2025.
- Notable investors include Keiretsu Forum, Elevate Ventures, Tech Council Ventures, Angel Physicians Fund, Angels + Life.Sci Investors Network — 8 tracked in total.
- Sword Bio has filed 1 Form D with the SEC, most recently Jun 2023 ($50K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Sword Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Sword Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sword Bio
Operator of bioanalytical contract research organization (CRO) designed to determine and monitor the value of biological markers. The company's offers specialized services such as assay development, validation, and sample analysis to support pharmaceutical and biotech companies throughout drug development phases, enabling scientists to get more robust and reliable data and continue advances in medical research, drug discovery, and the provision of healthcare products and services.
- Sector
- Healthcare
- HQ
- Carmel, IN, United States
- Founded
- 2004
- Employees
- 27
- Website
- swordbio.com/
- Ownership
- Privately Held (backing)
Sword Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sword Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sword Bio in its N-PORT filings yet. We sweep new filings monthly.